ArticleJACC. Case reports2026
Early Experience With the Septal Scoring Along the Midline Endocardium (SESAME) Technique in the Asia-Pacific Region.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSESAME (septal scoring along the midline endocardium) is a novel transcatheter electrosurgical technique for septal reduction. Experience with this technique in the Asia-Pacific region has not been previously described. CASE SUMMARY: We report 4 cases of SESAME procedures performed in the Asia-Pacific region. The procedures encompassed diverse clinical scenarios, including standalone treatment for hypertrophic obstructive cardiomyopathy (HOCM) in patients with persistent symptoms despite prior alcohol septal ablation or lack of suitable septal branches, and as an adjunct to transcatheter aortic valve replacement (TAVR) in patients with concomitant severe aortic stenosis and septal hypertrophy. The procedures were successfully completed in all cases with reduction in left ventricular outflow tract (LVOT) gradients. One patient developed high-grade atrioventricular block requiring permanent pacemaker implantation. At follow-up ranging from 1 to 3 months, patients demonstrated improved LVOT gradients and functional status. TAKE-HOME MESSAGES: This case series demonstrates the feasibility of SESAME in the Asia-Pacific region for various indications including standalone HOCM treatment and prevention of LVOT obstruction in conjunction with TAVR. Further multicenter studies are needed to evaluate the long-term outcomes and safety profile of this emerging technique in diverse patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.